Details
Stereochemistry | ACHIRAL |
Molecular Formula | C19H23N5O3 |
Molecular Weight | 369.4176 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC(NCC2=C(C)C3=C(N)N=C(N)N=C3C=C2)=CC(OC)=C1OC
InChI
InChIKey=NOYPYLRCIDNJJB-UHFFFAOYSA-N
InChI=1S/C19H23N5O3/c1-10-11(5-6-13-16(10)18(20)24-19(21)23-13)9-22-12-7-14(25-2)17(27-4)15(8-12)26-3/h5-8,22H,9H2,1-4H3,(H4,20,21,23,24)
Trimetrexate, a second-generation folate antagonist which was used under brand name NEUTREXIN with concurrent leucovorin administration (leucovorin protection) was indicated as an alternative therapy for the treatment of moderate-to-severe Pneumocystis carinii pneumonia (PCP) in immunocompromised patients, including patients with the acquired immunodeficiency syndrome (AIDS). Nevertheless, this product was discontinued. In present time, trimetrexate with a different combinations is in the phase II of clinical trial for the treatment the following cancer diseases: pancreatic cancer and colorectal cancer (in combination with fluorouracil and leucovorin) and to treat a refractory acute leukemia in combination with leucovorin. Trimetrexate is a competitive inhibitor of dihydrofolate reductase (DHFR) from bacterial, protozoan, and mammalian sources. DHFR catalyzes the reduction of intracellular dihydrofolate to the active coenzyme tetrahydrofolate. Inhibition of DHFR results in the depletion of this coenzyme, leading directly to interference with thymidylate biosynthesis, as well as inhibition of folate-dependent formyltransferases, and indirectly to inhibition of purine biosynthesis. The result is disruption of DNA, RNA, and protein synthesis, with consequent cell death.
Originator
Sources: http://adisinsight.springer.com/drugs/800000868
Curator's Comment: # Pfizer
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1926 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11448221 |
|||
Target ID: P00374 Gene ID: 1719.0 Gene Symbol: DHFR Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/12649191 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | NEUTREXIN Approved UseNeutrexin (trimetrexate glucuronate for injection) with concurrent leucovorin administration (leucovorin protection) is indicated as an alternative therapy for the treatment of moderate-to-severe Pneumocystis carinii pneumonia (PCP) in immunocompromised patients, including patients with the acquired immunodeficiency syndrome (AIDS), who are intolerant of, or are refractory to, trimethoprim-sulfamethoxazole therapy or for whom trimethoprim-sulfamethoxazole is contraindicated. This indication is based on the results of a randomized, controlled double-blind trial comparing Neutrexin with concurrent leucovorin protection (TMTX/LV) to trimethoprim sulfamethoxazole (TMP/SMX) in patients with moderate-to-severe Pneumocystis carinii pneumonia, as well as results of a Treatment IND. Launch Date7.5608641E11 |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3.1 mg/L |
30 mg/m² 1 times / day steady-state, intravenous dose: 30 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered: LEUCOVORIN CALCIUM |
TRIMETREXATE plasma | Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
15.8 mg × h/L |
30 mg/m² 1 times / day steady-state, intravenous dose: 30 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered: LEUCOVORIN CALCIUM |
TRIMETREXATE plasma | Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
11 h |
30 mg/m² 1 times / day steady-state, intravenous dose: 30 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered: LEUCOVORIN CALCIUM |
TRIMETREXATE plasma | Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
100 mg/m2 1 times / week multiple, intravenous MTD Dose: 100 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 100 mg/m2, 1 times / week Sources: |
unhealthy, 49 years n = 1 Health Status: unhealthy Condition: pulmonary and pleural metastasis from cutaneous angiosarcoma Age Group: 49 years Sex: F Population Size: 1 Sources: |
Disc. AE: Death... AEs leading to discontinuation/dose reduction: Death (grade 5) Sources: |
75 mg/m2 single, intravenous MTD Dose: 75 mg/m2 Route: intravenous Route: single Dose: 75 mg/m2 Sources: |
unhealthy, 63 years n = 1 Health Status: unhealthy Condition: adenocarcinoma of the lung Age Group: 63 years Sex: F Population Size: 1 Sources: |
Disc. AE: Death... AEs leading to discontinuation/dose reduction: Death (grade 5) Sources: |
10 mg/m2 1 times / day steady, intravenous MTD Dose: 10 mg/m2, 1 times / day Route: intravenous Route: steady Dose: 10 mg/m2, 1 times / day Sources: |
unhealthy, adult n = 17 Health Status: unhealthy Condition: solid cancer Age Group: adult Sex: unknown Population Size: 17 Sources: |
Other AEs: Gastrointestinal signs and symptoms... |
100 mg/m2 1 times / week multiple, intravenous MTD Dose: 100 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 100 mg/m2, 1 times / week Sources: |
unhealthy, adult n = 4 Health Status: unhealthy Condition: solid cancer Age Group: adult Sex: unknown Population Size: 4 Sources: |
DLT: Myelosuppression... Other AEs: Hematotoxicity... Dose limiting toxicities: Myelosuppression Other AEs:Hematotoxicity (grade 3, 2 patients) Sources: |
110 mg/m2 1 times / week multiple, intravenous MTD Dose: 110 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 110 mg/m2, 1 times / week Sources: |
unhealthy, adult n = 3 Health Status: unhealthy Condition: solid cancer Age Group: adult Sex: unknown Population Size: 3 Sources: |
DLT: Myelosuppression... |
130 mg/m2 1 times / week multiple, intravenous MTD Dose: 130 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 130 mg/m2, 1 times / week Sources: |
unhealthy, adult n = 7 Health Status: unhealthy Condition: solid cancer Age Group: adult Sex: unknown Population Size: 7 Sources: |
DLT: Myelosuppression... Disc. AE: Hematotoxicity... Dose limiting toxicities: Myelosuppression AEs leading todiscontinuation/dose reduction: Hematotoxicity (grade 2, 2 patients) Sources: |
15 mg/m2 single, intravenous MTD Dose: 15 mg/m2 Route: intravenous Route: single Dose: 15 mg/m2 Sources: |
unhealthy, adult n = 18 Health Status: unhealthy Condition: solid cancer Age Group: adult Sex: unknown Population Size: 18 Sources: |
Other AEs: Gastrointestinal signs and symptoms... |
155 mg/m2 1 times / week multiple, intravenous (max) MTD Dose: 155 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 155 mg/m2, 1 times / week Sources: |
unhealthy, adult n = 29 Health Status: unhealthy Condition: solid cancer Age Group: adult Sex: unknown Population Size: 29 Sources: |
Disc. AE: Hematotoxicity... AEs leading to discontinuation/dose reduction: Hematotoxicity (grade 2, 12 patients) Sources: |
155 mg/m2 1 times / week multiple, intravenous MTD Dose: 155 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 155 mg/m2, 1 times / week Sources: |
unhealthy, adult n = 2 Health Status: unhealthy Condition: solid cancer Age Group: adult Sex: unknown Population Size: 2 Sources: |
DLT: Myelosuppression... |
50 mg/m2 1 times / week multiple, intravenous MTD Dose: 50 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 50 mg/m2, 1 times / week Sources: |
unhealthy, adult n = 7 Health Status: unhealthy Condition: solid cancer Age Group: adult Sex: unknown Population Size: 7 Sources: |
DLT: Myelosuppression... |
75 mg/m2 1 times / week multiple, intravenous MTD Dose: 75 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 75 mg/m2, 1 times / week Sources: |
unhealthy, adult n = 8 Health Status: unhealthy Condition: solid cancer Age Group: adult Sex: unknown Population Size: 8 Sources: |
DLT: Myelosuppression... |
90 mg/m2 1 times / week multiple, intravenous MTD Dose: 90 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 90 mg/m2, 1 times / week Sources: |
unhealthy, adult n = 6 Health Status: unhealthy Condition: solid cancer Age Group: adult Sex: unknown Population Size: 6 Sources: |
DLT: Myelosuppression... Disc. AE: Hematotoxicity... Dose limiting toxicities: Myelosuppression AEs leading todiscontinuation/dose reduction: Hematotoxicity (grade 2, 1 patient) Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Death | grade 5 Disc. AE |
100 mg/m2 1 times / week multiple, intravenous MTD Dose: 100 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 100 mg/m2, 1 times / week Sources: |
unhealthy, 49 years n = 1 Health Status: unhealthy Condition: pulmonary and pleural metastasis from cutaneous angiosarcoma Age Group: 49 years Sex: F Population Size: 1 Sources: |
Death | grade 5 Disc. AE |
75 mg/m2 single, intravenous MTD Dose: 75 mg/m2 Route: intravenous Route: single Dose: 75 mg/m2 Sources: |
unhealthy, 63 years n = 1 Health Status: unhealthy Condition: adenocarcinoma of the lung Age Group: 63 years Sex: F Population Size: 1 Sources: |
Gastrointestinal signs and symptoms | 10 mg/m2 1 times / day steady, intravenous MTD Dose: 10 mg/m2, 1 times / day Route: intravenous Route: steady Dose: 10 mg/m2, 1 times / day Sources: |
unhealthy, adult n = 17 Health Status: unhealthy Condition: solid cancer Age Group: adult Sex: unknown Population Size: 17 Sources: |
|
Myelosuppression | DLT | 100 mg/m2 1 times / week multiple, intravenous MTD Dose: 100 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 100 mg/m2, 1 times / week Sources: |
unhealthy, adult n = 4 Health Status: unhealthy Condition: solid cancer Age Group: adult Sex: unknown Population Size: 4 Sources: |
Hematotoxicity | grade 3, 2 patients | 100 mg/m2 1 times / week multiple, intravenous MTD Dose: 100 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 100 mg/m2, 1 times / week Sources: |
unhealthy, adult n = 4 Health Status: unhealthy Condition: solid cancer Age Group: adult Sex: unknown Population Size: 4 Sources: |
Myelosuppression | DLT | 110 mg/m2 1 times / week multiple, intravenous MTD Dose: 110 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 110 mg/m2, 1 times / week Sources: |
unhealthy, adult n = 3 Health Status: unhealthy Condition: solid cancer Age Group: adult Sex: unknown Population Size: 3 Sources: |
Myelosuppression | DLT | 130 mg/m2 1 times / week multiple, intravenous MTD Dose: 130 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 130 mg/m2, 1 times / week Sources: |
unhealthy, adult n = 7 Health Status: unhealthy Condition: solid cancer Age Group: adult Sex: unknown Population Size: 7 Sources: |
Hematotoxicity | grade 2, 2 patients Disc. AE |
130 mg/m2 1 times / week multiple, intravenous MTD Dose: 130 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 130 mg/m2, 1 times / week Sources: |
unhealthy, adult n = 7 Health Status: unhealthy Condition: solid cancer Age Group: adult Sex: unknown Population Size: 7 Sources: |
Gastrointestinal signs and symptoms | 15 mg/m2 single, intravenous MTD Dose: 15 mg/m2 Route: intravenous Route: single Dose: 15 mg/m2 Sources: |
unhealthy, adult n = 18 Health Status: unhealthy Condition: solid cancer Age Group: adult Sex: unknown Population Size: 18 Sources: |
|
Hematotoxicity | grade 2, 12 patients Disc. AE |
155 mg/m2 1 times / week multiple, intravenous (max) MTD Dose: 155 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 155 mg/m2, 1 times / week Sources: |
unhealthy, adult n = 29 Health Status: unhealthy Condition: solid cancer Age Group: adult Sex: unknown Population Size: 29 Sources: |
Myelosuppression | DLT | 155 mg/m2 1 times / week multiple, intravenous MTD Dose: 155 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 155 mg/m2, 1 times / week Sources: |
unhealthy, adult n = 2 Health Status: unhealthy Condition: solid cancer Age Group: adult Sex: unknown Population Size: 2 Sources: |
Myelosuppression | DLT | 50 mg/m2 1 times / week multiple, intravenous MTD Dose: 50 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 50 mg/m2, 1 times / week Sources: |
unhealthy, adult n = 7 Health Status: unhealthy Condition: solid cancer Age Group: adult Sex: unknown Population Size: 7 Sources: |
Myelosuppression | DLT | 75 mg/m2 1 times / week multiple, intravenous MTD Dose: 75 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 75 mg/m2, 1 times / week Sources: |
unhealthy, adult n = 8 Health Status: unhealthy Condition: solid cancer Age Group: adult Sex: unknown Population Size: 8 Sources: |
Myelosuppression | DLT | 90 mg/m2 1 times / week multiple, intravenous MTD Dose: 90 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 90 mg/m2, 1 times / week Sources: |
unhealthy, adult n = 6 Health Status: unhealthy Condition: solid cancer Age Group: adult Sex: unknown Population Size: 6 Sources: |
Hematotoxicity | grade 2, 1 patient Disc. AE |
90 mg/m2 1 times / week multiple, intravenous MTD Dose: 90 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 90 mg/m2, 1 times / week Sources: |
unhealthy, adult n = 6 Health Status: unhealthy Condition: solid cancer Age Group: adult Sex: unknown Population Size: 6 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes | likely (co-administration study) Comment: concomitant administration of SPORANOX (itraconazole) and trimetrexate may inhibit the metabolism of trimetrexate |
PubMed
Title | Date | PubMed |
---|---|---|
Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugs. | 1992 Sep |
|
Expression and characterization of recombinant human-derived Pneumocystis carinii dihydrofolate reductase. | 2000 Nov |
|
Marked suppression of the activity of some, but not all, antifolate compounds by augmentation of folate cofactor pools within tumor cells. | 2001 Apr 1 |
|
RD114-pseudotyped oncoretroviral vectors. Biological and physical properties. | 2001 Jun |
|
A meta-analysis of salvage therapy for Pneumocystis carinii pneumonia. | 2001 Jun 25 |
|
Synthesis of 2,4-diamino-6-(thioarylmethyl)pyrido[2,3-d]pyrimidines as dihydrofolate reductase inhibitors. | 2001 Nov |
|
Methylthioadenosine phosphorylase as target for chemoselective treatment of T-cell acute lymphoblastic leukemic cells. | 2002 Jan-Feb |
|
Resistance to multiple novel antifolates is mediated via defective drug transport resulting from clustered mutations in the reduced folate carrier gene in human leukaemia cell lines. | 2002 Nov 1 |
|
Analysis of quinazoline and pyrido[2,3-d]pyrimidine N9-C10 reversed-bridge antifolates in complex with NADP+ and Pneumocystis carinii dihydrofolate reductase. | 2002 Sep |
|
Quinoxaline chemistry. Part 15. 4-[2-Quinoxalylmethylenimino]-benzoylglutamates and -benzoates, 4-[2-quinoxalylmethyl-N-methylamino]-benzoylglutamates as analogues of classical antifolate agents. Synthesis, elucidation of structures and in vitro evaluation of antifolate and anticancer activities. | 2003 Jan |
|
Chemotherapy for malignant pleural mesothelioma: past results and recent developments. | 2003 Jan 27 |
|
Sulfa resistance and dihydropteroate synthase mutants in recurrent Pneumocystis carinii pneumonia. | 2003 Jul |
|
A new nonlinear mixture response surface paradigm for the study of synergism: a three drug example. | 2003 Oct |
|
Design, synthesis, and biological evaluation of 2,4-diamino-5-methyl-6-substituted-pyrrolo[2,3-d]pyrimidines as dihydrofolate reductase inhibitors. | 2004 Jul 1 |
|
Dihydropteroate synthase gene mutations in Pneumocystis and sulfa resistance. | 2004 Oct |
|
Prediction of genotoxicity of chemical compounds by statistical learning methods. | 2005 Jun |
|
Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates. | 2006 Dec |
|
Quantitative correlation between promoter methylation and messenger RNA levels of the reduced folate carrier. | 2008 May 1 |
|
Clinical efficacy of first- and second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia: a tri-centre cohort study. | 2009 Dec |
|
Structures of dihydrofolate reductase-thymidylate synthase of Trypanosoma cruzi in the folate-free state and in complex with two antifolate drugs, trimetrexate and methotrexate. | 2009 Jul |
|
The immunobiology of cord blood transplantation. | 2010 Dec |
|
Gateways to clinical trials. | 2010 Dec |
|
Application and review of the separate ray model to investigate interaction effects. | 2010 Jan 1 |
|
Comparison of methods for statistical analysis of combination studies. | 2010 Jan 1 |
|
Cancer chemotherapy: targeting folic acid synthesis. | 2010 Nov 19 |
Sample Use Guides
Neutrexin (trimetrexate glucuronate for injection) is administered at a dose of 45 mg/m2 once daily by intravenous infusion over 60 minutes. Leucovorin must be administered daily during treatment with Neutrexin and for 72 hours past the last dose of Neutrexin. Leucovorin may be administered intravenously at a dose of 20 mg/m2 over 5 to 10 minutes every 6 hours for a total daily dose of 80 mg/m2, or orally as 4 doses of 20 mg/m2 spaced equally throughout the day. The oral dose should be rounded up to the next higher 25 mg increment. The recommended course of therapy is 21 days of Neutrexin and 24 days of leucovorin.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2529027
Carboxypeptidase G2 (CPG2), an enzyme produced by Pseudomonas strain RS-16, hydrolyzes the glutamate residue from methotrexate and other folates. The possibility of enhancing trimetrexate cytotoxicity by CPG2 induced folate depletion was investigated in vitro in a human leukemia cell line, CCRF-CEM, and in three sublines of these cells each with a different methotrexate resistance phenotype. Trimetrexate alone was cytotoxic against the parent and all the resistant cell lines with the drug concentrations required to decrease the cell count to 50% of control in the nanomolar range (1.4, 1.6, 1.5, and 0.7 nM in CCRF-CEM, CCRF-CEM/E, CCRF-CEM/P, and CCRF-CEM/T, respectively) following 5 days of exposure.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
P01AX07
Created by
admin on Fri Dec 15 15:55:10 UTC 2023 , Edited by admin on Fri Dec 15 15:55:10 UTC 2023
|
||
|
LIVERTOX |
NBK548765
Created by
admin on Fri Dec 15 15:55:10 UTC 2023 , Edited by admin on Fri Dec 15 15:55:10 UTC 2023
|
||
|
FDA ORPHAN DRUG |
132299
Created by
admin on Fri Dec 15 15:55:10 UTC 2023 , Edited by admin on Fri Dec 15 15:55:10 UTC 2023
|
||
|
NCI_THESAURUS |
C2153
Created by
admin on Fri Dec 15 15:55:10 UTC 2023 , Edited by admin on Fri Dec 15 15:55:10 UTC 2023
|
||
|
NCI_THESAURUS |
C511
Created by
admin on Fri Dec 15 15:55:10 UTC 2023 , Edited by admin on Fri Dec 15 15:55:10 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB11312MIG
Created by
admin on Fri Dec 15 15:55:10 UTC 2023 , Edited by admin on Fri Dec 15 15:55:10 UTC 2023
|
PRIMARY | |||
|
5103
Created by
admin on Fri Dec 15 15:55:10 UTC 2023 , Edited by admin on Fri Dec 15 15:55:10 UTC 2023
|
PRIMARY | |||
|
C1314
Created by
admin on Fri Dec 15 15:55:10 UTC 2023 , Edited by admin on Fri Dec 15 15:55:10 UTC 2023
|
PRIMARY | |||
|
6545
Created by
admin on Fri Dec 15 15:55:10 UTC 2023 , Edited by admin on Fri Dec 15 15:55:10 UTC 2023
|
PRIMARY | |||
|
52128-35-5
Created by
admin on Fri Dec 15 15:55:10 UTC 2023 , Edited by admin on Fri Dec 15 15:55:10 UTC 2023
|
PRIMARY | |||
|
42333
Created by
admin on Fri Dec 15 15:55:10 UTC 2023 , Edited by admin on Fri Dec 15 15:55:10 UTC 2023
|
PRIMARY | RxNorm | ||
|
D016597
Created by
admin on Fri Dec 15 15:55:10 UTC 2023 , Edited by admin on Fri Dec 15 15:55:10 UTC 2023
|
PRIMARY | |||
|
100000076926
Created by
admin on Fri Dec 15 15:55:10 UTC 2023 , Edited by admin on Fri Dec 15 15:55:10 UTC 2023
|
PRIMARY | |||
|
UPN4ITI8T4
Created by
admin on Fri Dec 15 15:55:10 UTC 2023 , Edited by admin on Fri Dec 15 15:55:10 UTC 2023
|
PRIMARY | |||
|
7613
Created by
admin on Fri Dec 15 15:55:10 UTC 2023 , Edited by admin on Fri Dec 15 15:55:10 UTC 2023
|
PRIMARY | |||
|
5583
Created by
admin on Fri Dec 15 15:55:10 UTC 2023 , Edited by admin on Fri Dec 15 15:55:10 UTC 2023
|
PRIMARY | |||
|
DB01157
Created by
admin on Fri Dec 15 15:55:10 UTC 2023 , Edited by admin on Fri Dec 15 15:55:10 UTC 2023
|
PRIMARY | |||
|
CHEMBL119
Created by
admin on Fri Dec 15 15:55:10 UTC 2023 , Edited by admin on Fri Dec 15 15:55:10 UTC 2023
|
PRIMARY | |||
|
m11163
Created by
admin on Fri Dec 15 15:55:10 UTC 2023 , Edited by admin on Fri Dec 15 15:55:10 UTC 2023
|
PRIMARY | Merck Index | ||
|
249008
Created by
admin on Fri Dec 15 15:55:10 UTC 2023 , Edited by admin on Fri Dec 15 15:55:10 UTC 2023
|
PRIMARY | |||
|
DTXSID3023714
Created by
admin on Fri Dec 15 15:55:10 UTC 2023 , Edited by admin on Fri Dec 15 15:55:10 UTC 2023
|
PRIMARY | |||
|
2757
Created by
admin on Fri Dec 15 15:55:10 UTC 2023 , Edited by admin on Fri Dec 15 15:55:10 UTC 2023
|
PRIMARY | |||
|
TRIMETREXATE
Created by
admin on Fri Dec 15 15:55:10 UTC 2023 , Edited by admin on Fri Dec 15 15:55:10 UTC 2023
|
PRIMARY | |||
|
UPN4ITI8T4
Created by
admin on Fri Dec 15 15:55:10 UTC 2023 , Edited by admin on Fri Dec 15 15:55:10 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)